USPTO Grants JBKLAB Cancer Treatment Patent US12605382B2
Summary
The USPTO granted US Patent 12605382B2 to JBKLAB Co., Ltd. for a pharmaceutical composition containing 2,6-dichloro-4-(4-(4-hydroxycyclohexylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenol as an active ingredient, classified under CPC A61P 35/00 for cancer treatment. The patent, filed on May 3, 2022, contains 12 claims and covers the use of the compound alone and in combination with radiotherapy or other anticancer drugs.
“In addition, a compound of example 1, according to the present invention, exhibits synergistic anticancer effects when combined with radiotherapy or other anticancer drugs in a breast cancer cell line and a liver cancer cell line, and thus can be developed as an anticancer drug or a food exhibiting excellent effects in the treatment of cancer.”
What changed
The USPTO issued Patent 12605382B2 to JBKLAB Co., Ltd., covering a novel anticancer compound that demonstrated efficacy comparable to or greater than sorafenib and etoposide in breast and liver cancer cell lines, with synergistic effects when combined with radiotherapy.
Pharmaceutical companies and oncology researchers should note this IP issuance: JBKLAB now holds enforceable patent rights in the US market for this therapeutic compound, potentially affecting competing research programs and licensing negotiations in the cancer treatment space.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Pharmaceutical composition for preventing, alleviating, or treating cancer containing 2,6-dichloro-4-(4-(4-hydroxycyclohexylamino)-7H- pyrrolo[2,3-d]pyrimidin-5-yl)phenol as active ingredient
Grant US12605382B2 Kind: B2 Apr 21, 2026
Assignee
JBKLAB Co., Ltd.
Inventors
Bong Keun Jang
Abstract
The present invention relates to a pharmaceutical composition for preventing or treating cancer, containing 2,6-dichloro-4-(4-(4-hydroxycyclohexylamino)-7H-pyrrolo[2,3-D]pyrimidin-5-yl)phenol as an active ingredient. It has been ascertained that the present invention inhibits the formation of mammospheres in a breast cancer cell line and, when compared to anticancer drugs sorafenib and etoposide, which are topoisomerase inhibitors widely used in lung cancer, ovarian cancer, colon cancer, melanoma and the like, exhibits remarkable effects greater than or equal to those of the anticancer drugs sorafenib and etoposide. In addition, a compound of example 1, according to the present invention, exhibits synergistic anticancer effects when combined with radiotherapy or other anticancer drugs in a breast cancer cell line and a liver cancer cell line, and thus can be developed as an anticancer drug or a food exhibiting excellent effects in the treatment of cancer.
CPC Classifications
A61K 31/519 A61K 33/243 A61K 31/365 A61P 35/00
Filing Date
2022-05-03
Application No.
18288896
Claims
12
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.